Actively Recruiting
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
Led by Menarini Silicon Biosystems, INC · Updated on 2026-03-18
187
Participants Needed
1
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA/RNA (cfDNA/RNA) analysis.
CONDITIONS
Official Title
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have invasive breast cancer with evidence of advanced metastatic or unresectable disease
- Have HR+/HER2 negative or triple negative breast cancer before starting first line therapy or beyond in the metastatic setting
- Or have HER2 positive breast cancer before starting second line therapy or beyond in the metastatic setting
- Have CTC HER2, ER, PD-L1, and cfDNA/RNA tests ordered as part of routine care
- Be 18 years of age or older
You will not qualify if you...
- Are pregnant
- Cannot provide blood samples as judged by the treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
Research Team
M
Marija Balic, MD, PhD, MBA
CONTACT
L
Lisette Stork-Sloots
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here